Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting-Reference-Cited by-同舟云学术

Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life setting

Published:2017-09-27 Issue:3 Volume:233 Page:2313-2323
ISSN:0021-9541
Container-title:Journal of Cellular Physiology
language:en
Short-container-title:J Cell Physiol

Author:

Gamucci Teresa¹,Pizzuti Laura²,Sperduti Isabella³,Mentuccia Lucia¹,Vaccaro Angela¹,Moscetti Luca⁴,Marchetti Paolo⁵,Carbognin Luisa⁶,Michelotti Andrea⁷,Iezzi Laura⁸,Cassano Alessandra⁹,Grassadonia Antonino⁸,Astone Antonio⁹,Botticelli Andrea⁵,Magnolfi Emanuela¹,Di Lauro Luigi²,Sergi Domenico²,Fuso Paola⁹,Tinari Nicola⁸,Barba Maddalena²,Maugeri-Saccà Marcello²,Landucci Elisabetta⁷,Conti Francesca²,Sanguineti Giuseppe¹⁰,De Tursi Michele⁸,Iafrate Gianni¹¹,Giordano Antonio¹²¹³,Ciliberto Gennaro¹⁴,Natoli Clara⁸,Vici Patrizia²^ORCID

Affiliation:

1. Medical Oncology Unit, ASL Frosinone; Frosinone Italy

2. Division of Medical Oncology 2; IRCCS Regina Elena National Cancer Institute; Rome Italy

3. IRCCS Regina Elena National Cancer Institute; Bio-Statistics Unit; Rome Italy

4. Division of Medical Oncology, Department of Oncology and Hematology; University Hospital of Modena; Modena Italy

5. Medical Oncology Unit Policlinico Sant'Andrea; Rome Italy

6. Medical Oncology, University of Verona; Azienda Ospedaliera Universitaria Integrata; Verona Italy

7. UO Oncologia Medica I, Ospedale S. Chiara, Dipartimento di oncologia, dei trapianti e delle nuove tecnologie; Azienda Ospedaliera Universitaria Pisana; Pisa Italy

8. Department of Medical, Oral and Biotechnological Sciences; Centro Scienze dell'Invecchiamento e Medicina Traslazionale − CeSI-MeT; University G. D'Annunzio; Chieti Italy

9. Department of Medical Oncology; Catholic University of Sacred Heart; Rome Italy

10. Department of Radiotherapy; IRCCS Regina Elena National Cancer Institute; Rome Italy

11. UOSD Oncologic Surgery; Ospedaletto SS Trinità; Sora Lazio Italy

12. Department of Medicine, Surgery and Neuroscience; University of Siena and Istituto Toscano Tumori (ITT); Siena Italy

13. Sbarro Institute for Cancer Research and Molecular Medicine, Department of Biology, College of Science and Technology; Temple University; Philadelphia Pennsylvania

14. Scientific Direction; IRCCS Regina Elena National Cancer Institute; Rome Italy

Funder

Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO)

Publisher

Wiley

Subject

Cell Biology,Clinical Biochemistry,Physiology

Reference42 articles.

1. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy;Ács;Diagnostic Pathology,2017

2. Basal-like and triple-negative breast cancers: A critical review with an emphasis on the implications for pathologists and oncologists;Badve;Modern Pathology,2011

3. Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer;Barba;BMC Cancer,2017

4. A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer;Bria;Lung Cancer,2009

5. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer;Byrski;Breast Cancer Research,2012

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. H3K27ac-induced RHOXF2 activates Wnt2/β-catenin pathway by binding to HOXC13 to aggravate the malignant progression of triple negative breast cancer;Cellular Signalling;2024-08

2. Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer;Breast Cancer Research;2024-01-18

3. Prognostic predictive value of Ki-67 in stage I–II triple-negative breast cancer;Future Science OA;2023-11-23

4. PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning;Breast Cancer Research;2023-11-13

5. A Retrospective Exploratory Analysis for Serum Extracellular Vesicles Reveals APRIL (TNFSF13), CXCL13, and VEGF-A as Prognostic Biomarkers for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer;International Journal of Molecular Sciences;2023-10-25